Medicare AdvantagePrior AuthMedium impact
Qutenza® (capsaicin) 8% patch (Revised)
Humana·Pain Management, Neurology, Endocrinology +2 more·Medicare Advantage
Effective date
Jan 1, 2026
We identified it
Jun 24, 2026
Summary
Humana Medicare Advantage has revised its prior authorization policy for Qutenza (capsaicin) 8% patch, effective January 1, 2026. The policy requires specific diagnostic criteria and failed trials of other medications before approval for postherpetic neuralgia (PHN) and diabetic peripheral neuropathy (DPN).
Action Required
By January 1, 2026: Billing and clinical teams must update prior authorization workflows for Qutenza (capsaicin) 8% patch prescriptions. For PHN patients, ensure documentation of neuropathic pain diagnosis and trials/contraindications to two drugs from anticonvulsant or tricyclic antidepressant classes. For DPN patients, document diabetic peripheral neuropathy of feet diagnosis and previous treatment with at least two of: gabapentin, duloxetine, lidocaine 5% patch, or pregabalin. Update EMR templates to capture required documentation. Claims without proper prior authorization will be denied.